Detalhe da pesquisa
1.
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Br J Cancer
; 113(4): 585-94, 2015 Aug 11.
Artigo
Inglês
| MEDLINE | ID: mdl-26171933
2.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
N Engl J Med
; 361(8): 766-76, 2009 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-19692688
3.
Radiofrequency ablation as a substitute for surgery in elderly patients with nonresected breast cancer: pilot study with long-term outcomes.
Radiology
; 264(2): 597-605, 2012 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-22692040
4.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Lancet Oncol
; 12(12): 1101-8, 2011 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22018631
5.
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.
Lancet Oncol
; 12(6): 527-39, 2011 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-21570352
6.
Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients.
Ann Surg Oncol
; 18(5): 1372-9, 2011 May.
Artigo
Inglês
| MEDLINE | ID: mdl-21108045
7.
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.
Oncologist
; 15(8): 799-809, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20671105
8.
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).
Breast Cancer Res Treat
; 123(2): 453-61, 2010 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-20632084
9.
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.
Breast Cancer Res Treat
; 117(1): 69-75, 2009 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-19030986
10.
D2-40 in breast cancer: should we detect more vascular emboli?
Mod Pathol
; 22(2): 216-22, 2009 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-18820667
11.
Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations.
Mod Pathol
; 22(3): 403-9, 2009 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-19060846
12.
First-line capecitabine monotherapy for slowly progressing metastatic breast cancer: do we need aggressive treatment?
Oncology
; 77(5): 318-27, 2009.
Artigo
Inglês
| MEDLINE | ID: mdl-19940523
13.
A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
Clin Cancer Res
; 14(6): 1744-52, 2008 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18347175
14.
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
N Engl J Med
; 353(26): 2747-57, 2005 Dec 29.
Artigo
Inglês
| MEDLINE | ID: mdl-16382061
15.
Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Lancet Oncol
; 8(12): 1071-1078, 2007 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-18024211
16.
Epithelial atypia in biopsies performed for microcalcifications. practical considerations about 2,833 serially sectioned surgical biopsies with a long follow-up.
Virchows Arch
; 451(1): 1-10, 2007 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-17551752
17.
Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial.
Anticancer Res
; 27(4C): 2689-96, 2007.
Artigo
Inglês
| MEDLINE | ID: mdl-17695434
18.
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
Lancet Oncol
; 12(2): 116, 2011 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-21277543
19.
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
J Clin Oncol
; 23(19): 4265-74, 2005 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15911866
20.
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Cancer Res
; 63(19): 6523-31, 2003 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-14559846